Zhu Yongyun, Zhang Mingxiang, Liu Xin, Xie Min, Xiang Honggang, Zhu Zheng-Zhi
Department of General Surgery, Pudong New Area People's Hospital, Shanghai, 201299, People's Republic of China.
Department of Pulmonary and Critical Care Medicine, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, People's Republic of China.
Mol Biotechnol. 2025 Jun;67(6):2239-2245. doi: 10.1007/s12033-024-01191-w. Epub 2024 Jun 7.
The objective of our study was to use quantum dots for the purpose of seeing and detecting C-C motif chemokine ligand 5 (CCL5) inside the tissue of sentinel lymph nodes (SLN) and primary tumors. This endeavor aimed to enhance the accuracy of predicting the condition of non-sentinel lymph nodes and provide valuable insights for making informed treatment choices. We analyzed breast cancer patients who underwent sentinel lymph node biopsy followed by axillary lymph node removal due to one or two positive sentinel lymph nodes at the Second People's Hospital of Wuhu, China, between August 2018 and July 2022. Quantum dot technology was employed to visualize and determine CCL5 in the tissue samples from 84 patients. Out of a group diagnosed with breast cancer, 208 underwent sentinel lymph node biopsy. From this pool, 84 tested positive and subsequently underwent axillary lymph node removal. The presence of distinct orange-red fluorescence, linked to quantum dots, was evident in the cellular components of both primary tumors and positive sentinel lymph node tissues. We found a significant relationship between higher levels of SLNCCL5 and advanced tumor growth (P < 0.05). To understand the predictive value of SLN CCL5 related to non-sentinel lymph node status, we utilized the receiver operating characteristic (ROC) method. The area under the curve (AUC) calculated was 0.745 with a cutoff point of 23.285. Multivariate logistic regression was used to understand the effect of tumor dimensions and SLNCCL5 levels on non-sentinel lymph node status in specific patients. Both the size of the tumor and SLNCCL5 levels were found to have a significant impact (P < 0.05). Data suggested that the presence of positive SLNCCL5 might serve as an assessment parameter for anticipating the condition of non-SLN in cases of breast cancer involving T1 or T2 tumors with one or two positive sentinel lymph nodes.
我们研究的目的是利用量子点来观察和检测前哨淋巴结（SLN）和原发性肿瘤组织内的C-C基序趋化因子配体5（CCL5）。这一努力旨在提高预测非前哨淋巴结状况的准确性，并为做出明智的治疗选择提供有价值的见解。我们分析了2018年8月至2022年7月在中国芜湖市第二人民医院因一两个前哨淋巴结阳性而接受前哨淋巴结活检并随后进行腋窝淋巴结清扫的乳腺癌患者。采用量子点技术对84例患者的组织样本中的CCL5进行可视化和测定。在一组被诊断为乳腺癌的患者中，208例接受了前哨淋巴结活检。其中，84例检测呈阳性，随后进行了腋窝淋巴结清扫。在原发性肿瘤和阳性前哨淋巴结组织的细胞成分中，明显存在与量子点相关的独特橙红色荧光。我们发现SLN CCL5水平较高与肿瘤进展显著相关（P < 0.05）。为了解SLN CCL5与非前哨淋巴结状态相关的预测价值，我们采用了受试者工作特征（ROC）方法。计算出的曲线下面积（AUC）为0.745，截断点为23.285。采用多变量逻辑回归来了解肿瘤大小和SLN CCL5水平对特定患者非前哨淋巴结状态的影响。发现肿瘤大小和SLN CCL5水平均有显著影响（P < 0.05）。数据表明，在伴有一两个前哨淋巴结阳性的T1或T2期乳腺癌病例中，阳性SLN CCL5的存在可能作为预测非SLN状况的评估参数。
